Movement Tracking Devices for Cancer Patients on Chemotherapy

Recruiting at 2 trial locations

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Southern California

Disqualifiers: Hematologic malignancy, Symptomatic brain metastases, Movement disorder, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

Duration: 60 days

41 Participants Needed

Trial Summary

What is the purpose of this trial?

This clinical trial studies movement tracking devices in optimizing and monitoring physical activity in patients with solid tumors undergoing chemotherapy in a health care facility during the day without spending the night. Movement tracking devices, such as Microsoft Kinect 2 and Microsoft Band 2, may help doctors learn about the health of cancer patients.

Research Team

Jorge Nieva

Principal Investigator

University of Southern California

Eligibility Criteria

This trial is for solid tumor patients undergoing chemotherapy who can consent, wear tracking devices, and report symptoms for up to 60 days. They must read English, Spanish or Mandarin, use a smartphone and wristband, be on specific chemo cycles without assistive walking devices. Excluded are those missing limbs, with symptomatic brain metastases or severe movement disorders.

Inclusion Criteria

Able to read English, Spanish, or Traditional Mandarin to complete patient reported outcomes

I am scheduled for at least 2 cycles of strong chemotherapy.

Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

I am missing one or more limbs.

I have been diagnosed with a blood cancer.

I have brain metastases that are causing symptoms.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants perform physical activities and wear movement tracking devices while completing PRO questionnaires and weighing themselves daily

60 days

2 visits (in-person) on days 1 and 21

Follow-up

Participants are monitored for safety and effectiveness after treatment

90 days

Treatment Details

Interventions

• Accelerometer

Trial Overview The study tests if movement tracking devices like Microsoft Kinect 2 and Band 2 can help optimize physical activity monitoring in solid tumor patients receiving day chemotherapy. It involves wearing sensors and using technology to provide daily health data.

Participant Groups

Group I: Observational (physical activity, PROs) Experimental Treatment 4 Interventions

Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.

Who Is Running the Clinical Trial?

University of Southern California

Lead Sponsor

Trials

956

Recruited

1,609,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+